ClinicalTrials.gg
RecruitingNCT07080944SYMPHONYUpdated Jan 6, 2026

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC

An interventional study of SLN identification using technetium-99m and SLN intra-operatory identification with radioguided surgery in Invasive Breast Carcinoma, Sentinel Lymph Node Biopsy (SLNB) and Neoadjuvant Chemotherapy, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by European Institute of Oncology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Breast Neoplasms by European Institute of Oncology — 40 open to participants now, 48 under way, 2 of them phase 3. Breast Neoplasms · European Institute of Oncology.

Planned enrollment
25th of 37
75 · median 94
Started
2025
with 7 others
No phase
24 of 64
13 open now
Primary completion
2030-07
later than 45 of 47 live
Registered
59th of 64
by date

Among the 64 studies in Breast Neoplasms by European Institute of Oncology, this one is the 25th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2025, is one of 24 with no phase, reaches primary completion later than 45 of the 47 other live ones, and was the 59th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 64 studies in Breast Neoplasms by European Institute of Oncology are open now, in 1 country. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 40 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by European Institute of Oncology, or all of them as a file.
02

Study summary

This study will prospectively determine the feasibility and oncological safety of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in inflammatory breast cancer patients traditionally considered ineligible for SLNB due to locally advanced cancer with skin/chest wall involvement (cT4d) and heavy nodal burden at presentation (cN1/N2). This study will also assess the identification rate of sentinel lymph-node (SLN) (using single tracer mapping) after NACT in this patient population. Finally, the study will determine the long-term outcome of such cohort.

03

Conditions studied

  • Invasive Breast Carcinoma
  • Sentinel Lymph Node Biopsy (SLNB)
  • Neoadjuvant Chemotherapy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients over 18 years of age with clinically and -proven stage IIIB cT4d cN0-2 M0 breast cancer as assessed by clinical exam and imaging
  • Patients receiving NACT and having a nodal complete clinical response (ycN0) as assessed by physical exam and imaging (ultrasound and PET)
  • Ability to understand and willingness to sign document and comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Patients with cN3 stage at diagnosis
  • Participants with stage IV () breast cancer
  • Participants with positive contralateral axillary nodes identified on standard imaging studies (mammograpy, MRI, ultrasound) and cito-histologically ascertained
  • Patients with a prior history of ipsilateral breast cancer
  • Pregnant patients
  • Patients after NACT with persistent palpable axillary nodes, as assessed by physical exam, or with persistent pathological axillary nodes, as assessed by imaging
  • Patients not consenting to ALND
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Group 1

    Patients with SLN visualization.

    Procedure: SLN identification using technetium-99m

  • Experimental
    Group 2a

    Patients with no pre-surgery SLN visualization and intra-surgery SLN identification.

    Procedure: SLN intra-operatory identification with radioguided surgery

  • Active comparator
    Group 2b

    Patients with no pre-surgery SLN visualization and no intra-surgery SLN identification.

    Procedure: Axillary Limph Node Dissection (ALND)

Interventions

  • ProcedureSLN identification using technetium-99m

    SLN Biopsy after pre-surgery positive SLN visualization.

  • ProcedureSLN intra-operatory identification with radioguided surgery

    SLN biopsy after no pre-surgery SLN visualization using technetium-99m and intra-surgery SLN identification.

  • ProcedureAxillary Limph Node Dissection (ALND)

    Axillary Limph Node Dissection (ALND) after no pre-surgery SLN visualization using technetium-99m and no intra-surgery SLN identification.

06

What researchers measure

Primary outcomes

  1. intraoperative SLN identification rate.

    Evaluation of the feasibility of SLNB in a selected cohort of IBC patients operated who responded to systemic NACT in the axillary nodes, achieving complete clinical response (ycN0). The feasibility of SLNB, defined as the intraoperative SLN identification rate, will be calculated as the proportion of patients with successfully identified intraoperative SLNs among the enrolled patients.

    Time frame: 3 Months

Secondary outcomes

  1. Disease-free survival (DFS)

    DFS will be defined as the time from surgery to loco-regional recurrence, metastasis, other primary non-breast carcinomas, or death, whichever occurs first.

    Time frame: 5 years.

  2. Distant recurrence-free survival (DRFS)

    DRFS will be defined as the time from surgery to distant recurrence or death from any cause, whichever occurs first.

    Time frame: 5 years

  3. Breast cancer-specific survival (BCSS)

    BCSS will be defined as the time from surgery to death due to breast cancer.

    Time frame: 5 years

  4. Overall survival (OS)

    OS will be defined as the time from surgery to death from any cause.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2030, 55 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 55 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 23, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Jul 2030
CompletionEst.
Aug 2030
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07080944
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Dec 12, 2025
Primary completion
Jul 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Jan 6, 2026

Study contacts

Francesca Magnoni, MD
Contact
francesca.magnoni@ieo.it
+39 0294371092

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion